TY - JOUR
T1 - Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease
AU - Puchades, Maja
AU - Hansson, Sara Folkesson
AU - Nilsson, Carol L.
AU - Andreasen, Niels
AU - Blennow, Kaj
AU - Davidsson, Pia
N1 - Funding Information:
This work was supported by grants from the Swedish Medical Research Council (grants 12769, 13121), Stiftelsen Gamla tjänarinnor, the Swedish Society for Medical research, Stohnes Stifelsen, Stockholm, Sweden; Hjalmar Svensson Foundation, Lundgrens Vetenskapsfond, Adlerbertska forskningsfonden, Göteborg, Sweden and Alzheimerfonden, Lund, Sweden.
PY - 2003/10/21
Y1 - 2003/10/21
N2 - By comparing the cerebrospinal fluid (CSF) proteome between Alzheimer's disease (AD) patients and controls, it may be possible to identify proteins that play a role in the disease process and thus to study the pathogenesis of AD. Two-dimensional gel electrophoresis (2-DE), SYPRO Ruby staining and mass spectrometry were used for clinical screening of disease-influenced CSF proteins in AD patients compared to controls. In order to increase the detection of CSF proteins and to improve the separation of protein isoforms in a 2-D gel, micro-narrow range IPG strips were used. The levels of eight proteins and their isoforms, including apolipoprotein A1, apolipoprotein E, apolipoprotein J, β-trace, retinol-binding protein, kininogen, α-1 antitrypsin, cell cycle progression 8 protein, and α-1β glycoprotein were significantly altered in CSF of AD patients compared to controls. Furthermore, we also used liquid-phase IEF, as a prefractionation step, prior to 2-DE for comparison of CSF proteins between individual AD patients and controls. The levels of 37 proteins spots were altered in AD patients. One of the identified proteins, α-2-HS glycoprotein, has not previously been linked to AD. Our study shows that several glycoproteins are altered in AD.
AB - By comparing the cerebrospinal fluid (CSF) proteome between Alzheimer's disease (AD) patients and controls, it may be possible to identify proteins that play a role in the disease process and thus to study the pathogenesis of AD. Two-dimensional gel electrophoresis (2-DE), SYPRO Ruby staining and mass spectrometry were used for clinical screening of disease-influenced CSF proteins in AD patients compared to controls. In order to increase the detection of CSF proteins and to improve the separation of protein isoforms in a 2-D gel, micro-narrow range IPG strips were used. The levels of eight proteins and their isoforms, including apolipoprotein A1, apolipoprotein E, apolipoprotein J, β-trace, retinol-binding protein, kininogen, α-1 antitrypsin, cell cycle progression 8 protein, and α-1β glycoprotein were significantly altered in CSF of AD patients compared to controls. Furthermore, we also used liquid-phase IEF, as a prefractionation step, prior to 2-DE for comparison of CSF proteins between individual AD patients and controls. The levels of 37 proteins spots were altered in AD patients. One of the identified proteins, α-2-HS glycoprotein, has not previously been linked to AD. Our study shows that several glycoproteins are altered in AD.
KW - 2-DE
KW - Alzheimer's disease
KW - Cerebrospinal fluid
KW - Liquid-phase IEF
KW - Mass spectrometry
KW - Proteomics
UR - http://www.scopus.com/inward/record.url?scp=0141957321&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141957321&partnerID=8YFLogxK
U2 - 10.1016/j.molbrainres.2003.08.005
DO - 10.1016/j.molbrainres.2003.08.005
M3 - Article
C2 - 14559363
AN - SCOPUS:0141957321
SN - 0169-328X
VL - 118
SP - 140
EP - 146
JO - Molecular Brain Research
JF - Molecular Brain Research
IS - 1-2
ER -